JPMorgan Chase & Co. Purchases 45,381 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)

JPMorgan Chase & Co. raised its stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPRFree Report) by 419.5% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 56,199 shares of the biotechnology company’s stock after purchasing an additional 45,381 shares during the period. JPMorgan Chase & Co. owned approximately 0.12% of Capricor Therapeutics worth $855,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of CAPR. Virtu Financial LLC bought a new stake in Capricor Therapeutics in the third quarter worth about $458,000. Barclays PLC increased its holdings in Capricor Therapeutics by 106.6% in the 3rd quarter. Barclays PLC now owns 36,296 shares of the biotechnology company’s stock worth $552,000 after acquiring an additional 18,724 shares during the last quarter. Sphera Funds Management LTD. bought a new stake in Capricor Therapeutics in the 3rd quarter valued at about $938,000. State Street Corp boosted its position in Capricor Therapeutics by 27.8% during the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after purchasing an additional 111,291 shares during the period. Finally, Sassicaia Capital Advisers LLC purchased a new position in Capricor Therapeutics in the 3rd quarter valued at approximately $192,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on CAPR. Cantor Fitzgerald increased their price objective on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, January 2nd. Finally, Piper Sandler initiated coverage on Capricor Therapeutics in a report on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective for the company. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Capricor Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Check Out Our Latest Stock Report on Capricor Therapeutics

Capricor Therapeutics Trading Up 1.9 %

CAPR opened at $14.80 on Friday. The company has a market cap of $672.96 million, a price-to-earnings ratio of -13.96 and a beta of 4.08. The stock has a fifty day simple moving average of $15.06 and a two-hundred day simple moving average of $11.89. Capricor Therapeutics Inc has a 12-month low of $3.52 and a 12-month high of $23.40.

Capricor Therapeutics Profile

(Free Report)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

See Also

Institutional Ownership by Quarter for Capricor Therapeutics (NASDAQ:CAPR)

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.